This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2018
ASCO GU 2018
Prostate Cancer
Bladder Cancer
Renal Cancer
Penile, Urethral, Testicular and Adrenal Cancers
Press
ASCO GU 2018 Prostate Cancer
Viewing 61-80 of 88 articles
ASCO GU 2018: Impact of 2012 USPSTF Prostate Cancer Screening Recommendations on Prostate Cancer Detection and Presentation at Kaiser Permanente Northern California (KPNC)
ASCO GU 2018: Prospective Analysis of 4,474 Prostate Biopsies to Evaluate Potential Treatment Management Impact of Combined Clinical-genomic Risk Classification
ASCO GU 2018: Life After Prostate Cancer Diagnosis: One Step Beyond
ASCO GU 2018: Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer.
ASCO GU 2018: Review of First Presentation: SPARTAN and PROSPER
ASCO GU 2018: First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer
ASCO GU 2018: First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
ASCO GU 2018: Transcriptomic Heterogeneity of Androgen Receptor Activity in Primary Prostate Cancer: Identification and Characterization of a Low AR-active Subclass
ASCO GU 2018: Medical Resource Utilization of Abiraterone Acetate Plus Prednisone added to ADT in Metastatic Castration-naive Prostate Cancer: Results from LATITUDE
ASCO GU 2018: Management of Oligometastatic Prostate Cancer From Imaging to Therapy
ASCO GU 2018: Impact of Decipher test on adjuvant and salvage treatments received following radical prostatectomy
ASCO GU 2018: TPS383 - ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-sensitive Prostate Cancer
ASCO GU 2018: Shared decision making for prostate cancer screening: Reality or farce?
ASCO GU 2018: The FALCON Trial: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer
ASCO GU 2018: Emerging Immunotherapy Strategies for Castrate Resistant Prostate Cancer
ASCO GU 2018: Improving risk-stratification of localized prostate cancer in a prospective active surveillance cohort
ASCO GU 2018: Enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic CRPC patients metastatic to bone (PEACE III)
ASCO GU 2018: Molecular Therapies in Bone Metastases
ASCO GU 2018: Genomic and Phenotypic Evidence for Prostate Cancer Osteomimicry in Circulating Tumor Cells from Men with Metastatic Castration Resistant Prostate Cancer Treated with Radium-223
ASCO GU 2018: Multivitamin Use and Risk of Prostate Cancer Recurrence: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free